RU94020614A - Antitumor agent - Google Patents

Antitumor agent

Info

Publication number
RU94020614A
RU94020614A RU94020614/14A RU94020614A RU94020614A RU 94020614 A RU94020614 A RU 94020614A RU 94020614/14 A RU94020614/14 A RU 94020614/14A RU 94020614 A RU94020614 A RU 94020614A RU 94020614 A RU94020614 A RU 94020614A
Authority
RU
Russia
Prior art keywords
water
nitrosourea
chloroethyl
bis
polyvinylpyrrolidone
Prior art date
Application number
RU94020614/14A
Other languages
Russian (ru)
Other versions
RU2066181C1 (en
Inventor
Н.А. Оборотова
А.П. Полозкова
Н.М. Перетолчина
Г.К. Герасимова
В.Ф. Петровский
Original Assignee
Онкологический научный центр им.Н.Н.Блохина РАМН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Онкологический научный центр им.Н.Н.Блохина РАМН filed Critical Онкологический научный центр им.Н.Н.Блохина РАМН
Priority to RU94020614A priority Critical patent/RU2066181C1/en
Publication of RU94020614A publication Critical patent/RU94020614A/en
Application granted granted Critical
Publication of RU2066181C1 publication Critical patent/RU2066181C1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

FIELD: pharmacy, antitumors agents. SUBSTANCE: agent based on 1,3-bis-(2-chloroethyl)-1-nitrosourea has additionally low-molecular polyvinylpyrrolidone (molecular mass is 12600), ethanol and water at the following ratio of components, wt.-%: 1,3--bis-(2-chloroethyl)-1-nitrosourea 0.50-0.74; polyvinylpyrrolidone (molecular mass is 12600) 19-21; 95% ethanol 4.8-6.0, and water for injection up to 100. Agent can be used for treatment of malignant neoplasma. EFFECT: increased stability, safety, decreased by-side effects, preparing water-soluble medicinal form.

Claims (1)

Изобретение относится к лекарственным средствам, в частности к противоопухолевым препаратам, и может быть использовано в химиотерапевтической практике для лечения злокачественных новообразований. Предлагаемое лекарственное средство на основе [1,3 бис-(2 хлорэтил)- 1-нитрозомочевины отличается тем, что, с целью повышения стабильности, получения водорастворимой инъекционной лекарственной формы, повышения безопасности для больного, снижения побочных эффектов, обеспечения возможности длительного внутривенного введения, оно дополнительно содержит поливинилпирролидон низкомолекулярный (ммоль 12 600), этанол и воду при следующем содержании компонентов, мас.%: [1,3 бис-(2 хлорэтил)-1-нитрозомочевина 0,50 - 0,74; поливинилпирролидон (ммоль 12 600) 19,00 - 21,00; спирт этиловый 95% 4,80 - 6,00; вода для инъекций до 100,00.The invention relates to medicines, in particular to antitumor drugs, and can be used in chemotherapeutic practice for the treatment of malignant neoplasms. The proposed drug based on [1,3 bis- (2 chloroethyl) - 1-nitrosourea is characterized in that, in order to increase stability, obtain a water-soluble injectable dosage form, increase safety for the patient, reduce side effects, provide the possibility of long-term intravenous administration, it additionally contains low molecular weight polyvinylpyrrolidone (mmol 12,600), ethanol and water in the following components, wt.%: [1,3 bis- (2 chloroethyl) -1-nitrosourea 0.50 - 0.74; polyvinylpyrrolidone (mmol 12 600) 19.00 - 21.00; ethyl alcohol 95% 4.80 - 6.00; water for injection up to 100.00.
RU94020614A 1994-06-02 1994-06-02 Antitumor agent RU2066181C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU94020614A RU2066181C1 (en) 1994-06-02 1994-06-02 Antitumor agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU94020614A RU2066181C1 (en) 1994-06-02 1994-06-02 Antitumor agent

Publications (2)

Publication Number Publication Date
RU94020614A true RU94020614A (en) 1996-08-27
RU2066181C1 RU2066181C1 (en) 1996-09-10

Family

ID=20156724

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94020614A RU2066181C1 (en) 1994-06-02 1994-06-02 Antitumor agent

Country Status (1)

Country Link
RU (1) RU2066181C1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2699558C2 (en) * 2018-10-05 2019-09-06 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ Радиологии" Минздрава России РФ) Agent for targeted therapy of malignant growths

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043628A1 (en) * 1997-04-02 1998-10-08 Viktor Veniaminovich Tets Antitumoral drugs (chlonidan)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2699558C2 (en) * 2018-10-05 2019-09-06 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ Радиологии" Минздрава России РФ) Agent for targeted therapy of malignant growths

Also Published As

Publication number Publication date
RU2066181C1 (en) 1996-09-10

Similar Documents

Publication Publication Date Title
NO863620L (en) PROCEDURE FOR PREPARING A PHARMACEUTICAL PREPARATION
JPS63139136A (en) Enhancer for transdermal transmission of general medicine
IT1261849B (en) MEDICAL DEVICE FOR THE ADMINISTRATION OF ACTIVE INGREDIENTS OR VERY LOW DOSAGE DRUGS, IN PARTICULAR HOMEOPATHIC DRUGS.
KR960704543A (en) Parenteral Busulfan for treatment of malignant disease
ATE81287T1 (en) TARGETED ENTERAL DELIVERY SYSTEM.
CY1111088T1 (en) PHARMACEUTICAL FORM FOR TOLTERODIN ADMINISTRATION WITH CONTROLLED LIBERTY
ES2171469T3 (en) COMPOSITION ADMINISTERED BY NASAL AND PREPARATION THAT CONTAINS IT.
RU96122884A (en) HUMAN CANCER TREATMENT METHOD
KR970702728A (en) Cancer Treatment and Metastasis Prevention
BR9912356A (en) Treatment regimen for the administration of phenylacetylglutamine, phenylacetylisoglutamine, and / or phenylacetate
EP0795561A4 (en) Novel anthracycline compound derivatives and medicinal preparations containing the same
KR970025615A (en) Cancer metastasis inhibitor
RU95101385A (en) Products containing g-csf and tnf-binding protein
US3932624A (en) Method for prolonging the inhibitory effect of saralasin on angiotensin II
RU94020614A (en) Antitumor agent
KR860003018A (en) Medical treatment of non-viral diseases of human body using 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US3105793A (en) Injectable medicinal composition
KR830009776A (en) Induction of Cell Protection
KR870010871A (en) Intraoperative Treatment of Basal Cell Carcinoma by Recombinant Human Alpha Interferon
EP0728479A1 (en) Deacetyl moxisylyte in the treatment of acute urinary retention
GB0018322D0 (en) Pharmaceutical compositions
KR870005642A (en) Mixture of Diflunisal and Tromethamine
JPS5780317A (en) Preparation of pharmaceutical composition for injection
BR0113844A (en) Use of arginine in the preparation of a drug to prevent and treat side effects associated with intravenous drug administration.
KR900005980A (en) Anti-inflammatory α-[[(2-hydroxy-1,1-dimethyl-ethyl) amine] methyl] benzene methanol hydrochloride (EL-508)

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20090603